liver neoplasms

Summary

Summary: Tumors or cancer of the LIVER.

Top Publications

  1. pmc Gene expression in fixed tissues and outcome in hepatocellular carcinoma
    Yujin Hoshida
    Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA
    N Engl J Med 359:1995-2004. 2008
  2. ncbi Sorafenib in advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona
    N Engl J Med 359:378-90. 2008
  3. ncbi Hepatocellular carcinoma: epidemiology and molecular carcinogenesis
    Hashem B El-Serag
    Michael E DeBakey Veterans Administration Medical Center and Baylor College of Medicine, Houston Center for Quality of Care and Utilization Studies, Houston, Texas, USA
    Gastroenterology 132:2557-76. 2007
  4. ncbi Hepatocellular carcinoma
    Alejandro Forner
    Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic Barcelona, August Pi i Sunyer Biomedical Research Institute, University of Barcelona, Barcelona, Spain
    Lancet 379:1245-55. 2012
  5. ncbi Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
    Ann Lii Cheng
    National Taiwan University Hospital, Taipei, Taiwan
    Lancet Oncol 10:25-34. 2009
  6. ncbi Management of hepatocellular carcinoma
    Jordi Bruix
    BCLC Group Liver Unit Hospital Clínic, University of Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Hepatology 42:1208-36. 2005
  7. ncbi MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer
    Fanyin Meng
    Department of Internal Medicine, Scott and White Clinic, Texas A and M University System Health Science Center College of Medicine, Temple, Texas, USA
    Gastroenterology 133:647-58. 2007
  8. ncbi Hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Liver Unit, Digestive Disease Institute, IDIBAPS, Hospital Cli nic i Provincial, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain
    Lancet 362:1907-17. 2003
  9. pmc Production of infectious hepatitis C virus in tissue culture from a cloned viral genome
    Takaji Wakita
    Department of Microbiology, Tokyo Metropolitan Institute for Neuroscience, Tokyo 183 8526, Japan
    Nat Med 11:791-6. 2005
  10. pmc Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma
    Cecile Guichard
    Institut National de la Sante et de la Recherche Medicale INSERM, Unité Mixte de Recherche UMR 674, Génomique fonctionnelle des tumeurs solides, Paris, France
    Nat Genet 44:694-8. 2012

Detail Information

Publications326 found, 100 shown here

  1. pmc Gene expression in fixed tissues and outcome in hepatocellular carcinoma
    Yujin Hoshida
    Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA
    N Engl J Med 359:1995-2004. 2008
    ..An obstacle to the development of genome-based predictors of outcome in patients with hepatocellular carcinoma has been the lack of a means to carry out genomewide expression profiling of fixed, as opposed to frozen, tissue...
  2. ncbi Sorafenib in advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona
    N Engl J Med 359:378-90. 2008
    ..A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma...
  3. ncbi Hepatocellular carcinoma: epidemiology and molecular carcinogenesis
    Hashem B El-Serag
    Michael E DeBakey Veterans Administration Medical Center and Baylor College of Medicine, Houston Center for Quality of Care and Utilization Studies, Houston, Texas, USA
    Gastroenterology 132:2557-76. 2007
    ..A detailed understanding of epidemiologic factors and molecular mechanisms associated with HCC ultimately could improve our current concepts for screening and treatment of this disease...
  4. ncbi Hepatocellular carcinoma
    Alejandro Forner
    Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic Barcelona, August Pi i Sunyer Biomedical Research Institute, University of Barcelona, Barcelona, Spain
    Lancet 379:1245-55. 2012
    ..Research is active in the area of pathogenesis and treatment of hepatocellular carcinoma...
  5. ncbi Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
    Ann Lii Cheng
    National Taiwan University Hospital, Taipei, Taiwan
    Lancet Oncol 10:25-34. 2009
    ....
  6. ncbi Management of hepatocellular carcinoma
    Jordi Bruix
    BCLC Group Liver Unit Hospital Clínic, University of Barcelona, Institut d Investigacions Biomediques August Pi i Sunyer, Barcelona, Spain
    Hepatology 42:1208-36. 2005
  7. ncbi MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer
    Fanyin Meng
    Department of Internal Medicine, Scott and White Clinic, Texas A and M University System Health Science Center College of Medicine, Temple, Texas, USA
    Gastroenterology 133:647-58. 2007
    ..Although a role for aberrant miRNA expression in cancer has been postulated, the pathophysiologic role and relevance of aberrantly expressed miRNA to tumor biology has not been established...
  8. ncbi Hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Liver Unit, Digestive Disease Institute, IDIBAPS, Hospital Cli nic i Provincial, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain
    Lancet 362:1907-17. 2003
    ..Meta-analysis shows that only chemoembolisation improves survival in well-selected patients with unresectable HCC...
  9. pmc Production of infectious hepatitis C virus in tissue culture from a cloned viral genome
    Takaji Wakita
    Department of Microbiology, Tokyo Metropolitan Institute for Neuroscience, Tokyo 183 8526, Japan
    Nat Med 11:791-6. 2005
    ..The cell culture-generated HCV is infectious for chimpanzee. This system provides a powerful tool for studying the viral life cycle and developing antiviral strategies...
  10. pmc Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma
    Cecile Guichard
    Institut National de la Sante et de la Recherche Medicale INSERM, Unité Mixte de Recherche UMR 674, Génomique fonctionnelle des tumeurs solides, Paris, France
    Nat Genet 44:694-8. 2012
    ..This study provides insight into the somatic mutational landscape in HCC and identifies interactions between mutations in oncogene and tumor suppressor gene mutations related to specific risk factors...
  11. pmc Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model
    Janaiah Kota
    Center for Gene Therapy, The Research Institute at Nationwide Children s Hospital, Columbus, OH 43205, USA
    Cell 137:1005-17. 2009
    ..These findings suggest that delivery of miRNAs that are highly expressed and therefore tolerated in normal tissues but lost in disease cells may provide a general strategy for miRNA replacement therapies...
  12. pmc Epidemiology of viral hepatitis and hepatocellular carcinoma
    Hashem B El-Serag
    Section of Gastroenterology and Hepatology, Department of Medicine, Michael E DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Texas, USA
    Gastroenterology 142:1264-1273.e1. 2012
    ....
  13. ncbi The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
    Joseph F Perz
    Centers for Disease Control and Prevention, National Center for Infectious Diseases, Division of Viral Hepatitis, Epidemiology Branch, Atlanta, GA 30333, USA
    J Hepatol 45:529-38. 2006
    ..Chronic infections with hepatitis B virus (HBV) and hepatitis C virus (HCV) are well-recognized risk factors for cirrhosis and liver cancer, but estimates of their contributions to worldwide disease burden have been lacking...
  14. ncbi Hepatocellular carcinoma pathogenesis: from genes to environment
    Paraskevi A Farazi
    Department of Genetics, Division of Medical Sciences, Harvard University, Boston, Massachusetts 02115, USA
    Nat Rev Cancer 6:674-87. 2006
    ....
  15. pmc Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression
    Eek Joong Park
    Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA
    Cell 140:197-208. 2010
    ..The chronic inflammatory response caused by obesity and enhanced production of IL-6 and TNF may also increase the risk of other cancers...
  16. pmc miR-221 overexpression contributes to liver tumorigenesis
    Pascal Pineau
    Nuclear Organization and Oncogenesis Unit, Institut National de Santé et de Recherche Médicale U579, Institut Pasteur, 75724 Paris Cedex 15, France
    Proc Natl Acad Sci U S A 107:264-9. 2010
    ..Thus, the use of synthetic inhibitors of miR-221 may prove to be a promising approach to liver cancer treatment...
  17. pmc MicroRNA expression, survival, and response to interferon in liver cancer
    Junfang Ji
    Liver Carcinogenesis Section, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    N Engl J Med 361:1437-47. 2009
    ..Hepatocellular carcinoma is a common and aggressive cancer that occurs mainly in men. We examined microRNA expression patterns, survival, and response to interferon alfa in both men and women with the disease...
  18. ncbi Primary liver cancer: worldwide incidence and trends
    F Xavier Bosch
    Epidemiology and Cancer Registration Unit, IDIBELL Institut Català d Oncologia, Avda Gran Via s n, Km 2 7 08907 L Hospitalet de Llobregat, Barcelona, Spain
    Gastroenterology 127:S5-S16. 2004
    ..Primary liver cancer is the first human cancer largely amenable to prevention using hepatitis B virus vaccines and screening of blood and blood products for hepatitis B and C viruses...
  19. ncbi Modified RECIST (mRECIST) assessment for hepatocellular carcinoma
    Riccardo Lencioni
    Division of Diagnostic Imaging and Intervention, Department of Liver Transplantation, Hepatology, and Infectious Diseases, University of Pisa, Pisa, Italy
    Semin Liver Dis 30:52-60. 2010
    ..They are referred to herein as the modified RECIST assessment (mRECIST). Further studies are needed to confirm the accuracy of this measurement compared with conventional gold standards such as pathologic studies of explanted livers...
  20. ncbi Molecular pathogenesis of human hepatocellular carcinoma
    Snorri S Thorgeirsson
    Laboratory of Experimental Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Genet 31:339-46. 2002
    ..New strategies should enable these variants to be characterized...
  21. pmc Molecular targeted therapies in hepatocellular carcinoma
    Josep M Llovet
    Mount Sinai Liver Cancer Program, Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY, USA
    Hepatology 48:1312-27. 2008
    ..Ultimately, a molecular classification of HCC based on genome-wide investigations and identification of patient subclasses according to drug responsiveness will lead to a more personalized medicine...
  22. ncbi Hepatitis B virus infection--natural history and clinical consequences
    Don Ganem
    Department of Microbiology and Immunology and the Howard Hughes Medical Institute, University of California, San Francisco, USA
    N Engl J Med 350:1118-29. 2004
  23. ncbi Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma
    Jin Hou
    National Key Laboratory of Medical Immunology and Institute of Immunology, Second Military Medical University, Shanghai 200433, China
    Cancer Cell 19:232-43. 2011
    ..Our study provides miRNomes of human liver and HCC and contributes to better understanding of the important deregulated miRNAs in HCC and liver diseases...
  24. ncbi Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues
    Y Murakami
    Laboratory of Human Tumor Virus, Institute for Viral Research, Kyoto University, Kyoto, Japan
    Oncogene 25:2537-45. 2006
    ..This information may help clarify the molecular mechanisms involved in the progression of liver disease, potentially serving as a diagnostic tool of HCC...
  25. ncbi Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200
    Bruce J Giantonio
    University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 25:1539-44. 2007
    ..This study was conducted to determine the effect of bevacizumab (at 10 mg/kg) on survival duration for oxaliplatin-based chemotherapy in patients with previously treated metastatic colorectal cancer...
  26. pmc Hepatocellular carcinoma: A global view
    Ju Dong Yang
    Miles and Shirley Fiterman Center for Digestive Diseases, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Nat Rev Gastroenterol Hepatol 7:448-58. 2010
    ..Programs to provide targeted therapy at low cost, similar to the approach used for HIV therapy in the developing world, should be pursued...
  27. ncbi Rising incidence of hepatocellular carcinoma in the United States
    H B El-Serag
    Veterans Affairs Medical Center and the University of New Mexico, Albuquerque 87108, USA
    N Engl J Med 340:745-50. 1999
    ..S. vital-statistics data base to determine age-adjusted mortality rates from 1981 to 1995, and data from the Department of Veterans Affairs to determine age-adjusted rates of hospitalization for the disease from 1983 to 1997...
  28. ncbi MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity
    Hang Su
    Key Laboratory of Gene Engineering of the Ministry of Education, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat Sen University, Guangzhou, PR China
    Cancer Res 69:1135-42. 2009
    ..Taken together, our data suggest an important role of miR-101 in the molecular etiology of cancer and implicate the potential application of miR-101 in cancer therapy...
  29. ncbi Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
    Chien Jen Chen
    Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan
    JAMA 295:65-73. 2006
    ..Serum hepatitis B virus (HBV) DNA level is a marker of viral replication and efficacy of antiviral treatment in individuals with chronic hepatitis B...
  30. ncbi Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace
    GYORGY BAFFY
    VA Boston Healthcare System and Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    J Hepatol 56:1384-91. 2012
    ..This review summarizes current evidence as it pertains to the epidemiology, pathogenesis, and prevention of NAFLD-associated HCC...
  31. ncbi MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma
    F Fornari
    1Dipartimento di Medicina Interna e Gastroenterologia e Centro di Ricerca Biomedica Applicata, Universita di Bologna, Policlinico S Orsola, Bologna, Italy
    Oncogene 27:5651-61. 2008
    ..These findings establish a basis toward the development of therapeutic strategies aimed at blocking miR-221 in HCC...
  32. ncbi Design and endpoints of clinical trials in hepatocellular carcinoma
    Josep M Llovet
    HCC Translational Research Lab, Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clinic, CIBERehd, Institute for Biomedical Investigations August Pi Sunyer, Villarroel 170, 08036 Barcelona, Catalonia, Spain
    J Natl Cancer Inst 100:698-711. 2008
    ..These surrogate markers may help to enrich study populations and maximize the cost-benefit ratio of trial execution. Design and conduct of phase 3 trials should be coordinated by centers with appropriate expertise in HCC...
  33. pmc Targeted therapies for hepatocellular carcinoma
    Augusto Villanueva
    HCC Translational Research Laboratory, Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Liver Unit, Hospital Clinic, Barcelona, Catalonia, Spain
    Gastroenterology 140:1410-26. 2011
    ....
  34. ncbi Significance of CD90+ cancer stem cells in human liver cancer
    Zhen Fan Yang
    Center for Cancer Research and Department of Surgery, The University of Hong Kong, Pokfulam, Hong Kong, China
    Cancer Cell 13:153-66. 2008
    ..Differential gene expression profiles were identified in the CD45(-)CD90+ and CD45(-)CD90(-) cells isolated from tissue and blood samples from liver cancer patients and controls...
  35. pmc Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach
    Lars Zender
    Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA
    Cell 125:1253-67. 2006
    ..Our results establish a tractable model of liver cancer, identify two oncogenes that cooperate by virtue of their coamplification in the same genomic locus, and suggest an efficient strategy for the annotation of human cancer genes...
  36. ncbi The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective
    Alan P Venook
    Division of Medical Oncology, University of California San Francisco, San Francisco, California 94115, USA
    Oncologist 15:5-13. 2010
    ..A new and global approach to the study of HCC epidemiology is required if HCC disease prevention and treatment strategies are to be adequately directed and supported in coming years...
  37. ncbi Molecular mechanisms of hepatocellular carcinoma
    Rajagopal N Aravalli
    Department of Radiology, Cell Biology and Development, University of Minnesota Medical School, Minneapolis, MN, USA
    Hepatology 48:2047-63. 2008
    ..In this review, we discuss the contribution of these newer approaches toward an understanding of molecular mechanisms of HCC and for the development of novel cancer therapeutics...
  38. ncbi Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Liver Unit, Digestive Disease Institut, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic, Catalonia, Spain
    Hepatology 37:429-42. 2003
    ..In conclusion, chemoembolization improves survival of patients with unresectable HCC and may become the standard treatment. Treatment with tamoxifen does not modify the survival of patients with advanced disease...
  39. ncbi Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
    Li Liu
    Department of Cancer Biology, Bayer HealthCare Pharmaceuticals, West Haven, Connecticut 06516, USA
    Cancer Res 66:11851-8. 2006
    ....
  40. ncbi The role of signaling pathways in the development and treatment of hepatocellular carcinoma
    S Whittaker
    Dana Farber Cancer Institute, Boston, MA, USA
    Oncogene 29:4989-5005. 2010
    ..In addition, we also review the latest preclinical and clinical data on the rationally designed targeted agents that are now being directed against these pathways, with early evidence of success...
  41. ncbi Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma
    Yujuan Xiong
    Key Laboratory of Gene Engineering of the Ministry of Education, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat Sen University, China
    Hepatology 51:836-45. 2010
    ....
  42. ncbi Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma
    Timothy M Pawlik
    Johns Hopkins University School of Medicine, Baltimore, MD, USA
    J Clin Oncol 29:3960-7. 2011
    ..Toxicity is manageable with dose adjustment of sorafenib. Preliminary efficacy data are promising...
  43. ncbi Hepatocellular carcinoma in cirrhosis: incidence and risk factors
    Giovanna Fattovich
    Department of Gastroenterology, University of Verona, Verona, Italy
    Gastroenterology 127:S35-50. 2004
    ..Further studies are needed to investigate other viral factors (eg, HBV genotype/mutant, occult HBV, HIV coinfection) and preventable or treatable comorbidities (eg, obesity, diabetes) in the HCC risk in cirrhosis...
  44. ncbi Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection
    Qiang Gao
    Liver Cancer Institute, Zhong Shan Hospital and Shanghai Medical School, Fudan University, Key Laboratory for Carcinogenesis and Cancer Invasion, the Chinese Ministry of Education, Shanghai, People s Republic of China
    J Clin Oncol 25:2586-93. 2007
    ..To investigate the prognostic value of tumor-infiltrating lymphocytes (TILs), especially regulatory T cells (Tregs), in hepatocellular carcinoma (HCC) patients after resection...
  45. pmc NF-κB and STAT3 - key players in liver inflammation and cancer
    Guobin He
    Laboratory of Gene Regulation and Signal Transduction, School of Medicine, University of California at San Diego, 9500 Gilman Drive MC 0723, La Jolla, CA 92093 0723, USA
    Cell Res 21:159-68. 2011
    ..This review will focus on recent studies on the roles of NF-κB and STAT3 in liver cancer. Interactions between the two pathways and their potential as therapeutic targets will also be discussed...
  46. pmc p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2
    Taewan Kim
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, 2 Molecular, Cellular, and Developmental Biology Program, The Ohio State University, Columbus, OH 43210, USA
    J Exp Med 208:875-83. 2011
    ..Inhibition or overexpression of the miRNAs affects p53-regulated EMT by altering ZEB1 and ZEB2 expression. Our findings indicate that p53 can regulate EMT, and that p53-regulated miRNAs are critical mediators of p53-regulated EMT...
  47. ncbi Identification and characterization of tumorigenic liver cancer stem/progenitor cells
    Stephanie Ma
    Department of Pathology, The University of Hong Kong, Pokfulam, Hong Kong, China
    Gastroenterology 132:2542-56. 2007
    ..The aim of this study is to identify, isolate, and characterize the CSC population that drives and maintains hepatocellular carcinoma (HCC) growth and metastasis...
  48. ncbi Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma
    Chung Mau Lo
    Center for the Study of Liver Disease, University of Hong Kong Medical Center, Queen Mary Hospital, Hong Kong, China
    Hepatology 35:1164-71. 2002
    ..In conclusion, in Asian patients with unresectable hepatocellular carcinoma, transarterial Lipiodol chemoembolization significantly improves survival and is an effective form of treatment...
  49. pmc miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation
    Michela Garofalo
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    Cancer Cell 16:498-509. 2009
    ..Finally, we demonstrate that the MET oncogene is involved in miR-221&222 activation through the c-Jun transcription factor...
  50. pmc Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis
    Sunhwa Kim
    Department of Pharmacology and Cancer Center, School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093 0723, USA
    Nature 457:102-6. 2009
    ..These results explain how advanced cancer cells usurp components of the host innate immune system, including bone-marrow-derived myeloid progenitors, to generate an inflammatory microenvironment hospitable for metastatic growth...
  51. ncbi Identification of metastasis-related microRNAs in hepatocellular carcinoma
    Anuradha Budhu
    Liver Carcinogenesis Section, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Hepatology 47:897-907. 2008
    ..In addition, functional analysis of these miRNAs may enhance our biological understanding of HCC metastasis...
  52. ncbi Lamivudine for patients with chronic hepatitis B and advanced liver disease
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital and University, Taipei, Taiwan
    N Engl J Med 351:1521-31. 2004
    ..The effectiveness of antiviral therapy in preventing disease progression in patients with chronic hepatitis B and advanced fibrosis or cirrhosis is unknown...
  53. ncbi MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma
    Wei Chih Tsai
    Department of Biotechnology and Laboratory Science in Medicine, National Yang Ming University, Taipei, Taiwan, Republic of China
    Hepatology 49:1571-82. 2009
    ....
  54. pmc Lin28 promotes transformation and is associated with advanced human malignancies
    Srinivas R Viswanathan
    Children s Hospital Boston, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Harvard Stem Cell Institute, Boston, MA, USA
    Nat Genet 41:843-8. 2009
    ..Our work provides a mechanism for the coordinate repression of let-7 miRNAs observed in a subset of human cancers, and associates activation of LIN28 and LIN28B with poor clinical prognosis...
  55. pmc Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005
    Sean F Altekruse
    Division of Cancer Control and Population Sciences, and the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20892 8316, USA
    J Clin Oncol 27:1485-91. 2009
    ..Incidence rates are increasing in the United States. Monitoring incidence, survival, and mortality rates within at-risk populations can facilitate control efforts...
  56. ncbi Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma
    Mary Maluccio
    Department of Surgery, Medical Director, Indiana University Health Liver Oncology Program, Indiana University School of Medicine, Indianapolis, IN, USA
    CA Cancer J Clin 62:394-9. 2012
    ....
  57. ncbi miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma
    Mayuko Furuta
    Department of Molecular Cytogenetics, Medical Research Institute and School of Biomedical Science, Tokyo Medical and Dental University, Tokyo 113 8510, Japan
    Carcinogenesis 31:766-76. 2010
    ..Our results suggest that miR-124 and miR-203 are novel tumor-suppressive miRNAs for HCC epigenetically silenced and activating multiple targets during hepatocarcinogenesis...
  58. ncbi Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection
    Brad Q Starley
    Department of Medicine, Division of Gastroenterology and Hepatology, Brooke Army Medical Center, Fort Sam Houston, TX 78234, USA
    Hepatology 51:1820-32. 2010
    ..The complications of NASH, including cirrhosis and HCC, are expected to increase with the growing epidemic of diabetes and obesity...
  59. pmc Liver cirrhosis
    Detlef Schuppan
    Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Lancet 371:838-51. 2008
    ..This Seminar focuses on the diagnosis, complications, and management of cirrhosis, and new clinical and scientific developments...
  60. ncbi Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial
    Josep M Llovet
    Liver Unit, Digestive Disease Institute, Hospital Clinic, University of Barcelona, Barcelona, Spain
    Lancet 359:1734-9. 2002
    ..There is no standard treatment for unresectable hepatocellular carcinoma. Arterial embolisation is widely used, but evidence of survival benefits is lacking...
  61. pmc Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells
    Junfang Ji
    Liver Carcinogenesis Section, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Hepatology 50:472-80. 2009
    ..Taken together, our results define a novel regulatory link between miR-181s and human EpCAM(+) liver cancer stem/progenitor cells and imply that molecular targeting of miR-181 may eradicate HCC...
  62. ncbi Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma
    Elisa Wurmbach
    Mount Sinai Liver Cancer Program, Division of Hematology Oncology, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Hepatology 45:938-47. 2007
    ....
  63. pmc Hepatitis B virus biology
    C Seeger
    Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Microbiol Mol Biol Rev 64:51-68. 2000
    ..The state of knowledge in this very active field is therefore reviewed with an emphasis on past accomplishments as well as goals for the future...
  64. ncbi Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma
    Laura Gramantieri
    Dipartimento di Medicina Interna e Gastroenterologia e Centro di Ricerca Biomedica Applicata, Universita di Bologna, Bologna, Italy
    Cancer Res 67:6092-9. 2007
    ..These results indicate that cyclin G1 is a target of miR-122a and expand our knowledge of the molecular alterations involved in HCC pathogenesis and of the role of miRNAs in human cancer...
  65. ncbi Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model
    Elisa Callegari
    Dipartimento di Medicina Sperimentale e Diagnostica, Universita di Ferrara, Ferrara, Italy
    Hepatology 56:1025-33. 2012
    ..To validate the tumor-promoting effect of miR-221, we showed that in vivo delivery of anti-miR-221 oligonucleotides leads to a significant reduction of the number and size of tumor nodules...
  66. ncbi Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival
    Yu Sawada
    Section for Cancer Immunotherapy, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    Clin Cancer Res 18:3686-96. 2012
    ..In this nonrandomized, open-label, phase I clinical trial, we analyzed the safety and efficacy of GPC3 peptide vaccination in patients with advanced HCC...
  67. ncbi MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells
    Teng Xu
    Key Laboratory of Gene Engineering of the Ministry of Education, State Key Laboratory of Biocontrol, School of Life Sciences, Guangzhou, PR China
    Hepatology 50:113-21. 2009
    ..These results imply that miR-195 may block the G(1)/S transition by repressing Rb-E2F signaling through targeting multiple molecules, including cyclin D1, CDK6, and E2F3...
  68. ncbi MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations
    Yannick Ladeiro
    INSERM U674, Génomique fonctionnelle des tumeurs solides, Paris, France
    Hepatology 47:1955-63. 2008
    ..Thus, this strongly suggests that beta-catenin and HNF1alpha could regulate miR-375 and miR-107 expression levels, respectively...
  69. pmc EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features
    Taro Yamashita
    Liver Carcinogenesis Section, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Gastroenterology 136:1012-24. 2009
    ..We hypothesized that the heterogeneous nature of hepatocellular carcinoma (HCC), in part, may be owing to the presence of hepatic cancer cells with stem/progenitor features...
  70. ncbi CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway
    S Ma
    Department of Pathology, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China
    Oncogene 27:1749-58. 2008
    ..Targeting of this specific survival signaling pathway in CD133+ HCC CSCs may provide a novel therapeutic model for the disease...
  71. pmc Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis
    Jharna Datta
    Department of Molecular and Cellular Biochemistry, College of Pharmacy, and Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 68:5049-58. 2008
    ..The inhibition of cell cycle progression and induction of apoptosis after re-expression of miR-1 are some of the mechanisms by which DNA hypomethylating agents suppress hepatocarcinoma cell growth...
  72. ncbi Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers
    Hongxing Zhang
    State Key Laboratory of Proteomics, Beijing Proteome Research Center, Beijing Institute of Radiation Medicine, Beijing, China
    Nat Genet 42:755-8. 2010
    ..Our findings provide evidence that the 1p36.22 locus confers susceptibility to HBV-related HCC, and suggest that KIF1B-, UBE4B- or PGD-related pathways might be involved in the pathogenesis of this malignancy...
  73. ncbi A functional polymorphism in pre-microRNA-196a-2 contributes to the susceptibility of hepatocellular carcinoma in a Turkish population: a case-control study
    H Akkiz
    Department of Gastroenterology, Faculty of Medicine, Cukurova University, Adana, Turkey
    J Viral Hepat 18:e399-407. 2011
    ....
  74. ncbi Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma
    Elisabetta Bugianesi
    Department of Gastroenterology, Ospedale S Giovanni Battista, University of Turin, Turin, Italy
    Gastroenterology 123:134-40. 2002
    ..Nonalcoholic steatohepatitis (NASH) may progress to cirrhosis; whether NASH plays also a role in the development of hepatocellular carcinoma (HCC) is unknown...
  75. pmc Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival
    Jinmai Jiang
    College of Pharmacy, Ohio State University, Columbus, OH 43210, USA
    Clin Cancer Res 14:419-27. 2008
    ..MicroRNA (miRNA) is a new class of small, noncoding RNA. The purpose of this study was to determine if miRNAs are differentially expressed in hepatocellular carcinoma (HCC)...
  76. pmc Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases
    Eddie K Abdalla
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg 239:818-25; discussion 825-7. 2004
    ..To examine recurrence and survival rates for patients treated with hepatic resection only, radiofrequency ablation (RFA) plus resection or RFA only for colorectal liver metastases...
  77. pmc Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties
    C Coulouarn
    Laboratory of Experimental Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda 20892 4262, MD, USA
    Oncogene 28:3526-36. 2009
    ..From a clinical point of view, our study emphasizes miR-122 as a diagnostic and prognostic marker for HCC progression...
  78. ncbi Lysyl oxidase is essential for hypoxia-induced metastasis
    Janine T Erler
    Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California 94305, USA
    Nature 440:1222-6. 2006
    ..Furthermore, LOX may be required to create a niche permissive for metastatic growth. Our findings indicate that LOX is essential for hypoxia-induced metastasis and is a good therapeutic target for preventing and treating metastases...
  79. ncbi Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties
    Tetsuhiro Chiba
    Department of Regenerative Medicine, Graduate School of Medical Science, Yokohama City University, Yokohama, Japan
    Hepatology 44:240-51. 2006
    ..In conclusion, we propose that a minority population, detected as SP cells in HCC cells, possess extreme tumorigenic potential and provide heterogeneity to the cancer stem cell system characterized by distinct hierarchy...
  80. ncbi MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1
    Queenie W L Wong
    Department of Anatomical and Cellular Pathology at the Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, SAR Hong Kong, China
    Gastroenterology 135:257-69. 2008
    ..Recent studies have emphasized causative links between microRNA (miRNA) deregulations and cancer development. In hepatocellular carcinoma (HCC), information on differentially expressed miRNA remained largely undefined...
  81. pmc Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma
    Yujin Hoshida
    Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts 02142, USA
    Cancer Res 69:7385-92. 2009
    ..These experiments establish the first consensus classification framework for HCC based on gene expression profiles and highlight the power of integrating multiple data sets to define a robust molecular taxonomy of the disease...
  82. ncbi Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein
    Michiari Okuda
    Department of Physiology and Biophysics, University of Texas Medical Branch, Galveston, Texas 77555 0641, USA
    Gastroenterology 122:366-75. 2002
    ..Indirect evidence suggests that oxidative stress and mitochondrial injury play a role. The aim of this study was to determine if the HCV core protein itself alters mitochondrial function and contributes to oxidative stress...
  83. ncbi Gender disparity of hepatocellular carcinoma: the roles of sex hormones
    Shiou Hwei Yeh
    Department of Microbiology, National Taiwan University and Hospital, College of Medicine, Taipei, Taiwan
    Oncology 78:172-9. 2010
    ..Therefore, the ligand and the receptor factors of both sex hormones need to be included for assessing the relative risk of HCC patients of each gender...
  84. ncbi MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma
    Heike Varnholt
    Institute for Pathology, University Hospital Cologne, Cologne, Germany
    Hepatology 47:1223-32. 2008
    ..miR-122, miR-100, and miR-10a were overexpressed whereas miR-198 and miR-145 were up to 5-fold down-regulated in hepatic tumors compared to normal liver parenchyma...
  85. ncbi MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells
    Francesca Fornari
    Centro di Ricerca Biomedica Applicata e Dipartimento di Medicina Interna, Policlinico S Orsola Malpighi e Università di Bologna, Bologna, Italy
    Cancer Res 70:5184-93. 2010
    ..These results suggest that tactics to regulate mTOR and c-Met by elevating levels of miR-199a-3p may have therapeutic benefits in highly lethal cancers such as HCC...
  86. ncbi microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer
    C Braconi
    College of Medicine, and The Ohio State University Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA
    Oncogene 30:4750-6. 2011
    ....
  87. ncbi miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1
    Stephanie Ma
    Department of Pathology, Queen Mary Hospital, The University of Hong Kong, Hong Kong
    Cell Stem Cell 7:694-707. 2010
    ..Silencing TP53INP1 in CD133⁻ cells enhanced both self renewal and tumorigenicity in vivo. Collectively, miR-130b regulates CD133(+) liver TICs, in part, via silencing TP53INP1...
  88. pmc CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer
    Jiayi Wang
    Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, People Republic of China
    Nucleic Acids Res 38:5366-83. 2010
    ..The study elucidates that fine tuning of HULC expression is part of an auto-regulatory loop in which it's inhibitory to expression and activity of miR-372 allows lncRNA up-regulated expression in liver cancer...
  89. ncbi A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells
    Ju Seog Lee
    Lab of Experimental Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Room 4146, Bethesda, Maryland 20892, USA
    Nat Med 12:410-6. 2006
    ..Analyses of gene networks showed that activation of AP-1 transcription factors in this newly identified HCC subtype might have key roles in tumor development...
  90. ncbi Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma
    Shunsuke Ura
    Department of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan
    Hepatology 49:1098-112. 2009
    ....
  91. ncbi MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling
    Queenie W L Wong
    Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong, China
    Clin Cancer Res 16:867-75. 2010
    ..This study aims to profile the expressions of 156 microRNAs (miRNA) in hepatocellular carcinoma (HCC) and to characterize the functions of miR-222, the most significantly upregulated candidate identified...
  92. ncbi The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma
    Satoshi Shimizu
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, 2 2 Yamada oka, Suita, Osaka 565 0871, Japan
    J Hepatol 52:698-704. 2010
    ..The mechanisms underlying its dysregulation have not been clarified. In the present study, we explored the involvement of microRNAs that act as endogenous sequence-specific suppressors of gene expression...
  93. ncbi Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis
    Jian Xu
    State Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
    Mol Carcinog 50:136-42. 2011
    ..Our results indicate that serum miR-21, miR-122 and miR-223 are elevated in patients with HCC or chronic hepatitis and these miRNAs have strong potential to serve as novel biomarkers for liver injury but not specifically for HCC...
  94. ncbi Nonalcoholic fatty liver disease: from steatosis to cirrhosis
    Geoffrey C Farrell
    The Storr Liver Unit, Westmead s Millennium Institute, University of Sydney at Westmead Hospital, Westmead, NSW, Australia
    Hepatology 43:S99-S112. 2006
    ..Future challenges are to approach NAFLD as a preventive public health initiative and to motivate affected persons to adopt a healthier lifestyle...
  95. ncbi Hepatocellular carcinoma: current management and perspectives for the future
    Nuh N Rahbari
    Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Germany
    Ann Surg 253:453-69. 2011
    ..To review the literature on current management of hepatocellular carcinoma (HCC)...
  96. ncbi Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter
    Seung Oe Lim
    Department of Biological Sciences, Seoul National University, Seoul, Korea
    Gastroenterology 135:2128-40, 2140.e1-8. 2008
    ..We sought to determine whether ROS promote hypermethylation of the promoter region of E-cadherin, a regulator of the epithelial-to-mesenchymal transition, in hepatocellular carcinoma (HCC) cells...
  97. ncbi Hepatocellular carcinoma and hepatitis C in the United States
    Hashem B El-Serag
    Sections of Gastroenterology and Health Services Research at the Houston Department of Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX, 77030, USA
    Hepatology 36:S74-83. 2002
    ..Future research should focus on improving understanding of the incidence and risk factors for HCC, causes of HCV-related carcinogenesis, means of early detection, and better treatment for HCC...
  98. pmc TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3
    B Wang
    Department of Molecular and Cellular Biochemistry, Ohio State University, Columbus, OH 43210, USA
    Oncogene 29:1787-97. 2010
    ..miR-181b also enhanced resistance of HCC cells to the anticancer drug doxorubicin. On the basis of these results, we conclude that upregulation of miR-181b at early stages of feeding CDAA diet promotes hepatocarcinogenesis...
  99. ncbi Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma
    Mark Branda
    Liver Research Center, Department of Medicine, Rhode Island Hospital and Brown Medical School, Providence 02903, USA
    Hepatology 43:891-902. 2006
  100. ncbi Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Gastroenterology 131:1743-51. 2006
    ..We investigated the efficacy, safety, and resistance profile of adefovir dipivoxil treatment for up to 240 weeks...
  101. ncbi Polyploidization of liver cells
    Séverine Celton-Morizur
    Institut Cochin, Universite Paris Descartes, CNRS, UMR 8104, INSERM U567, Paris, France
    Adv Exp Med Biol 676:123-35. 2010
    ..Here we review the current state of understanding about how polyploidization is regulated during normal and pathological liver growth and detail by which mechanisms hepatocytes become polyploid...

Research Grants56

  1. Anti-Aging Mitochondrial Protein Therapy for Alzheimer?s Disease and Sarcopenia
    JAMES PEPPER BENNETT; Fiscal Year: 2010
    ..months (starting at 24 months) with rhTFAM therapy have improved motor function as well as lower incidence of liver neoplasms. At 30 months the treated mice have significantly increased motor performance and endurance (by 25% in ..
  2. Integrating plasma IGF-1 into novel classification of hepatocellular carcinoma
    Ahmed Kaseb; Fiscal Year: 2013
    ..Should we achieve our aims we may be able to develop new strategies in personalized therapy in better designed clinical trials of comparable criteria. ..
  3. Integration of RNAi, proteomic and chemical genetic approaches to identify specif
    Ramanuj DasGupta; Fiscal Year: 2009
    ..The primary goal of this project is to develop and implement new technologies in order to generate molecular tools that may be used to modulate the activity of the Wnt signaling pathway. ..
  4. Laser Device Development and Qualification to Enable Laser Tissue Welding
    CRAIG LENNON; Fiscal Year: 2010
    ..hemostasis and biliary sealing after liver resection surgery or hepatectomy for benign/primary/secondary liver neoplasms. The specific aim of the work is to demonstrate the feasibility of a prototype surgical laser system and ..
  5. Genetics pathways in intra-hepatic cholangiocarcinoma
    Aram F Hezel; Fiscal Year: 2013
    ..Moreover, many new models of disease and reagents produced by this study will enable others focused on research in this disease to make forward progress. ..
  6. GENDER EFFECTS ON SUSCEPTIBILITY TO LIVER NEOPLASIA
    David Hinton; Fiscal Year: 1999
    ..Understanding the gender sensitivity of medaka to hepatocarcinogenesis may provide valuable information about gender effects on cancer formation in other vertebrates and will further characterize the medaka model. ..
  7. Correlative Genetic Markers in Childhood Hepatoblastoma
    Gail Tomlinson; Fiscal Year: 2009
    ..This study will examine chromosome changes in 220 hepatoblastoma tumor specimens and will determine if these alterations can be used to predict patient outcome and hence guide future therapies. ..
  8. CELL CULTURE AND TRANSPLANTATION OF HUMAN HEPATOCYTES
    George Michalopoulos; Fiscal Year: 1993
    ..The effect of chemical carcinogen initiators and tumor promoters will also be examined in this transplantation system...
  9. Enhancement of Capecitabine by PHY906 in Liver Cancer
    Shwu Huey Liu; Fiscal Year: 2004
    ..The results of this study will help to guide the development of a clinical dosing regimen protocol and to support further investigations for future FDA approval. ..
  10. Multispectral Confocal and Image Analysis Facility
    Richard Cole; Fiscal Year: 2007
    ..The final project is developing better ways to analyze the three-dimensional images collected by the requested microscope by making advanced computer analysis available to all the microscope users. [unreadable] [unreadable] [unreadable]..
  11. PARTICULATE CONTRAST AGENTS FOR MRI
    David Stark; Fiscal Year: 1992
    ..LD50, iron metabolism, and other indices of potential toxicity will be used to decide which new materials are suitable for further development as contrast agents...
  12. Radiofrequency Tumor Ablation at Low Frequencies
    Dieter Haemmerich; Fiscal Year: 2009
    ..PUBLIC HEALTH RELEVANCE Successful completion of this project may result in a more effective treatment of cancer that will provide preferential heating and kill of cancer and sparing of normal tissue. ..
  13. Development of multi-probe radiofrequency ablation
    Fred Lee; Fiscal Year: 2009
    ..To accomplish these aims, an experienced multidisciplinary team at the University of Wisconsin, with collaborators at Harvard University and Valleylab, has been assembled. ..
  14. Tracked Laparoscopic Ultrasound for Use in Liver Surgery
    Philip Bao; Fiscal Year: 2004
    ..Ultimately, the success of this project may improve care for and expand the population who will benefit from surgical therapy of liver cancer. ..
  15. VIRAHEP-C Clinical Center
    Anna Lok; Fiscal Year: 2005
    ..abstract_text> ..
  16. THERAPY OF HEPATIC METASTASES FROM COLORECTAL CARCINOMA
    Nancy Kemeny; Fiscal Year: 2001
    ..Cryosurgery and newer hepatic arterial therapies are therapeutic modalities that can be used in patients in whom liver resection is impossible. ..
  17. RECURRENT HEPATITIS B AFTER LIVER TRANSPLANTATION
    Anna Lok; Fiscal Year: 2007
    ..abstract_text> ..
  18. Hepatitis Virus, Alcohol Exposure and Oxidative Stress
    Manal Hassan; Fiscal Year: 2002
    ..Serum Se, GPx activity, lipid peroxides and oxidative DNA damage will be measured in relation to HCV and alcohol intake history. ..
  19. Hepatic Arterial Flouridine and IV Bevacizumab for Primary Hepatic Malignancy
    William Jarnagin; Fiscal Year: 2008
    ..Furthermore, several important clinical issues are addressed by the proposed correlative studies, the results of which would be of broad general interest in clinical oncology. [unreadable] [unreadable] [unreadable]..
  20. Complications of Cirrhosis in American Patients
    Jorge Marrero; Fiscal Year: 2008
    ..I will supervise the conduct of the proposed research and meet with my mentors and advisors regularly. Completing this proposal will allow me to achieve my career goal and to contribute to an improve outcome of patients with HCC. ..
  21. Early Detection and Prognosis of Patients with Hepatocellular Carcinoma
    Jorge Marrero; Fiscal Year: 2008
    ..Therefore, identifying the risk factors, identifying new methods for early detection and determining prognosis for this tumor is of extreme importance. [unreadable] [unreadable]..
  22. Regulation of androgen metabolism by the nuclear receptor CAR
    Wendong Huang; Fiscal Year: 2008
    ..Manipulation of CAR activity by small molecules may be a novel approach for prostate cancer prevention and therapy. [unreadable] [unreadable] [unreadable]..
  23. Biologic Activity of Lycopene
    Xiang Dong Wang; Fiscal Year: 2002
    ..These studies will provide important information for the potential future use of lycopene as cancer preventive nutrient at different tissue sites and the knowledge of possible adverse effects with tobacco. ..
  24. Green Tea Targets COX-2/PGE2 and EFGR Pathways in NSCLC via Stimulating Annexin 1
    Qing Yi Lu; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  25. Novel HBV Therapeutic with Potential for Treatment of Drug-Resistant Infection
    Andrea Cuconati; Fiscal Year: 2008
    ..At the end of the proposed project, the novel compound would be ready for large-scale Phase III clinical testing with hepatitis B patients. [unreadable] [unreadable] [unreadable]..
  26. Therapy for Alpha-1AT Deficiency Liver Disease
    Jeffrey Teckman; Fiscal Year: 2009
    ..of these therapeutic strategies for future human trials, examine the mechanisms involved in inhibiting liver cell injury, and add to the understanding of the basic mechanisms of cellular injury in liver disease ..
  27. FAS/APO-1 MEDIATED APOPTOSIS
    Robert Fine; Fiscal Year: 2002
    ..Thus, the selective and rapid induction of apoptosis occurring only in cancer cells carrying p53 abnormalities could be a powerful therapeutic modality for the treatment of cancer. ..
  28. Metabolomic and Toxicogenetic Study of Ethanol Toxicity
    Ivan Rusyn; Fiscal Year: 2009
    ..abstract_text> ..
  29. Regulation of Bilirubin Metabolism by the Receptor CAR
    Wendong Huang; Fiscal Year: 2005
    ..The findings will elucidate the essential role of CAR in bilirubin metabolism and have significant implications for development of more potent drugs for the treatment of human jaundice and other related diseases. ..
  30. Lycopene Chemoprevention of Lung Cancer in Ferret
    Xiang Dong Wang; Fiscal Year: 2010
    ..In addition, the establishment of a lung carcinogenesis model in ferrets provides a valuable tool for both lung cancer and carotenoid research fields. ..
  31. Control of Eye Melanoma Metastsis
    Hans E Grossniklaus; Fiscal Year: 2010
    ..The third aim determines the mechanism of combined angiostatin/IFN control of the micrometastases using methods in the first two aims. ..
  32. FLOW CYTOMETRY INSTRUMENT
    ZUHAIR BALLAS; Fiscal Year: 2001
    ..abstract_text> ..
  33. KILLER CELLS AND ALCOHOL
    ZUHAIR BALLAS; Fiscal Year: 2008
    ..Preliminary data prompted the hypothesis that ETOH blunts the enhanced NK activity induced by CpG ODN [unreadable] [unreadable]..
  34. Pathophysiology of Arginine-induced Pancreatitis in Mice
    Ashok Saluja; Fiscal Year: 2006
    ..Successful completion of these studies will provide an excellent model of pancreatitis for future studies dealing with therapeutic interventions. ..
  35. THE ROLE OF IMMUNE RESPONSES IN ALCOHOLIC LIVER DISEASE
    THOMAS JERRELLS; Fiscal Year: 2007
    ..4. To define the role of NK cells in the hepatitis associated with MCMV infection of alcohol-fed mice. ..
  36. BIOCHEMISTRY AND IMMUNOLOGY OF ALCOHOLIC LIVER DISEASE
    THOMAS JERRELLS; Fiscal Year: 2004
    ..The ultimate goal of this training program is to prepare both basic scientists and clinically trained scientists for an active and productive research career on the effects of alcohol on the liver. ..
  37. DNA REPAIR AND SUSCEPTIBILITY TO ENVIRONMENTAL AGENTS
    Ivan Rusyn; Fiscal Year: 2004
    ..These experiments will also provide crucial mechanistic insights into possible differences in species- and tissue-specific responses to DNA damage induced by environmental agents. ..
  38. Colon and liver anticarcinogenicity by acetaminophen
    Gary Williams; Fiscal Year: 2004
    ..In addition, these experiments will provide support for the epidemiological observations of reduced cancer risk associated with the use of APAP. ..
  39. ALCOHOL INTAKE AND RETINOID METABOLISM AND SIGNALING
    Xiang Dong Wang; Fiscal Year: 2004
    ....
  40. IGF I, its receptor and vascular remodeling
    Jie Du; Fiscal Year: 2005
    ..Our results should have important practical consequences for the development of therapies to modulate vascular remodeling in hypertension ..
  41. A ROLE FOR VIRAL INFECTION IN ALCOHOLIC PANCREATITIS
    THOMAS JERRELLS; Fiscal Year: 2005
    ..The model system will also allow critical studies of possible therapeutic interventions. ..
  42. MECHANISM OF ETHANOL INDUCED IMPAIRMENTS IN IMMUNITY
    THOMAS JERRELLS; Fiscal Year: 2002
    ..By using the various infectious model systems in place in this laboratory the ETOH-mediated effects on the subsets of helper T cells (TH-1 and TH-2) will also be defined. ..
  43. Molecular Mechanisms of Phthalate-induced Carcinogenesis
    Ivan Rusyn; Fiscal Year: 2007
    ..This results in a "potentiation" of a non-specific mitogen release from Kupffer cells activated by lipid-like peroxisome proliferator particles, thus accounting for a characteristic burst of proliferation in the liver. ..
  44. Therapy for Liver Cancer by Targeting Energy Metabolism
    Jean Francois Geschwind; Fiscal Year: 2007
    ..This translational study combining the use of radiological and basic science research tools is both necessary and fundamental to firmly lay the groundwork for clinical trials. ..
  45. Control of Eye Melanoma Metastasis
    Hans Grossniklaus; Fiscal Year: 2003
    ..Both the IFN and angiostatin will prevent the progression of micrometastases into metastases by anti-angiogenesis. Angiostatin will prevent metastases by an anti-melanoma invasion effect. ..
  46. SUBMACULAR SURGERY TRIALS PATHOLOGY CENTER
    Hans Grossniklaus; Fiscal Year: 2003
    ..Additionally, eyes obtained post-mortem from patients enrolled in the SST will be studied for pathologic correlation with clinical findings and outcomes. ..
  47. Integrated Veterinary-Biomedical Research Training Pgm
    Ourania Andrisani; Fiscal Year: 2006
    ..This mentor diversity will facilitate recruitment and retention of students from minority and underrepresented groups while enriching the research education and training of all participating students. ..
  48. Computer Aided Liver Lesion Detection Algorithm
    Lawrence Schwartz; Fiscal Year: 2005
    ..Clearly this is the first step in a process of development and if successful will lead to further efforts in automated detection and characterization. ..
  49. cAMP Signaling in Sympathoadrenal Cell Development
    Ourania Andrisani; Fiscal Year: 2005
    ..Aim 2: To define the mechanism of the antagonistic effect of high-level activation of cAMP signaling on the BMP-2 mediated ASH-I gene expression and SA cell development. ..
  50. Molecular strategies to define carcinoids and rationalize surgical intervention
    Irvin Modlin; Fiscal Year: 2009
    ..This will provide novel biological information and provide molecular data to identify occult metastasis predict spread and facilitate preemptive appropriate therapy. ..
  51. Molecular Strategies for Gastric Carcinoid Surgery
    Irvin Modlin; Fiscal Year: 2005
    ..A pre-operative determination of the neoplastic ECL cell gene expression relating to gastrin responsiveness will improve the rationale for therapeutic gastric or antral resection. ..
  52. Non-Invasive Imaging of T Cell Trafficking
    Bernd Pichler; Fiscal Year: 2006
    ..abstract_text> ..
  53. Regulation of biliary secretion by purinergic signaling
    Andrew Feranchak; Fiscal Year: 2006
    ..The Mentored Clinical Scientist Development Award will provide the protected time, resources, and mentored environment to allow the applicant to achieve these goals. ..
  54. An Integrated PET-MRI System for Molecular Imaging
    Bernd Pichler; Fiscal Year: 2005
    ..abstract_text> ..